The stock has a 36-month beta value of 0.86. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for TARS is 35.71M, and at present, short sellers hold a 23.27% of that float. On May 25, 2025, the average trading volume of TARS was 730.03K shares.
TARS) stock’s latest price update
The stock of Tarsus Pharmaceuticals Inc (NASDAQ: TARS) has increased by 0.02 when compared to last closing price of 42.97. Despite this, the company has experienced a -1.65% fall in its stock price over the last five trading sessions. zacks.com reported 2025-05-14 that The heavy selling pressure might have exhausted for Tarsus Pharmaceuticals (TARS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
TARS’s Market Performance
TARS’s stock has fallen by -1.65% in the past week, with a monthly drop of -13.99% and a quarterly drop of -5.62%. The volatility ratio for the week is 1.80% while the volatility levels for the last 30 days are 2.97% for Tarsus Pharmaceuticals Inc The simple moving average for the past 20 days is -6.43% for TARS’s stock, with a -1.94% simple moving average for the past 200 days.
Analysts’ Opinion of TARS
Many brokerage firms have already submitted their reports for TARS stocks, with Goldman repeating the rating for TARS by listing it as a “Neutral.” The predicted price for TARS in the upcoming period, according to Goldman is $19 based on the research report published on November 20, 2023 of the previous year 2023.
William Blair, on the other hand, stated in their research note that they expect to see TARS reach a price target of $44. The rating they have provided for TARS stocks is “Outperform” according to the report published on July 18th, 2023.
TARS Trading at -10.02% from the 50-Day Moving Average
After a stumble in the market that brought TARS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.97% of loss for the given period.
Volatility was left at 2.97%, however, over the last 30 days, the volatility rate increased by 1.80%, as shares sank -14.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.51% lower at present.
During the last 5 trading sessions, TARS fell by -1.65%, which changed the moving average for the period of 200-days by +85.74% in comparison to the 20-day moving average, which settled at $45.93. In addition, Tarsus Pharmaceuticals Inc saw -22.38% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TARS starting from Azamian Bobak R., who sale 6,000 shares at the price of $50.00 back on Mar 24 ’25. After this action, Azamian Bobak R. now owns 824,106 shares of Tarsus Pharmaceuticals Inc, valued at $300,000 using the latest closing price.
Azamian Bobak R., the Officer of Tarsus Pharmaceuticals Inc, proposed sale 6,000 shares at $50.00 during a trade that took place back on Mar 24 ’25, which means that Azamian Bobak R. is holding shares at $300,000 based on the most recent closing price.
Stock Fundamentals for TARS
Current profitability levels for the company are sitting at:
- -0.47 for the present operating margin
- 0.93 for the gross margin
The net margin for Tarsus Pharmaceuticals Inc stands at -0.45. The total capital return value is set at -0.26. Equity return is now at value -33.98, with -24.69 for asset returns.
Currently, EBITDA for the company is -106.48 million with net debt to EBITDA at 1.79. When we switch over and look at the enterprise to sales, we see a ratio of 6.98. The receivables turnover for the company is 3.64for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.57.
Conclusion
To sum up, Tarsus Pharmaceuticals Inc (TARS) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
